The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Abdurasulova I.N.

FSBSI «Institute of Experimental Medicine», Moscow

Tarasova E.A.

FGBNU «Institut eksperimentalnoĭ meditsiny»;
OOO Nauchno-issledovatelskaja laboratorija «Diagnostika»

Nikiforova I.G.

Institut mozga cheloveka imeni N.P. Bekhterevoĭ RAN, Sankt-Peterburg

Il'ves A.G.

Ivashkova E.V.

Institut mozga cheloveka im. N.P. Behterevoĭ RAN, Sankt-Peterburg

Matsulevich A.V.

Institute of Experimental Medicine, St-Petersburg, Russia

Tatarinov A.E.

Institute of Experimental Medicine, St-Petersburg, Russia

Shangina L.V.

Institute of Experimental Medicine, St-Petersburg, Russia

Ermolenko E.I.

FGBNU «Institut eksperimentalnoĭ meditsiny»

Klimenko V.M.

Stoliarov I.D.

Suvorov A.N.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

The intestinal microbiota composition in patients with multiple sclerosis receiving different disease-modifying therapies DMT

Authors:

Abdurasulova I.N., Tarasova E.A., Nikiforova I.G., Il'ves A.G., Ivashkova E.V., Matsulevich A.V., Tatarinov A.E., Shangina L.V., Ermolenko E.I., Klimenko V.M., Stoliarov I.D., Suvorov A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8‑2): 62‑69

DOI: 10.17116/jnevro201811808262

Read: 4540 times

Download PDF (RU)
Contact the author
Table of contents

THE INTESTINAL MICROBIOTA COMPOSITION IN PATIENTS WITH MULTIPLE SCLEROSIS RECEIVING DIFFERENT DISEASE-MODIFYING THERAPIES DMT
THE INTESTINAL MICROBIOTA COMPOSITION IN PATIENTS WITH MULTIPLE SCLEROSIS RECEIVING DIFFERENT DISEASE-MODIFYING THERAPIES DMT

To cite this article:

Abdurasulova IN, Tarasova EA, Nikiforova IG, et al. . The intestinal microbiota composition in patients with multiple sclerosis receiving different disease-modifying therapies DMT. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8‑2):62‑69. (In Russ.)
https://doi.org/10.17116/jnevro201811808262

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Low-level laser therapy in multiple scle­rosis: justification and opti­mization methods of application. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):45-56
Dyna­mics of the condition of patients with premature ovarian insu­fficiency and the autoantibody profile before and after the use of new surgical technologies in complex treatment. Russian Journal of Human Reproduction. 2024;(5):25-34
Glial fibrillary acidic protein: is there a rela­tionship with the course of multiple scle­rosis and traumatic brain injury before the onset of multiple scle­rosis?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):80-84
An indi­vidual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102
Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18
The gut microbiota in bipo­lar diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33
Surgical treatment of seco­ndary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209
Quality of life of patients with multiple scle­rosis in the Smolensk region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):36-40
Nutrition, inte­stinal microbiota, and thyroid autoimmune pathology. Russian Journal of Preventive Medi­cine. 2025;(1):102-108
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Abstract:

Objective. To describe characteristics of the intestinal microbiota in patients with multiple sclerosis (MS) treated with glatiramer acetate (GA) or fingolimode (FG) for understanding causal relationships between gut microbiota and autoimmune processes in MS patients. Material and methods. The study included 34 patients treated with GA (n=17) or FG (n=17). GA was used in a dose of 20 mg/kg subcutaneously once a day, FG in a dose of 0.5 mg daily. All patients were examined during remission. To assess the composition of gut microbiota, bacteriological and real-time PCR techniques were used. DNA was extracted from feces using DNA-EXPRESS kit. Results and conclusion. There was a decrease in numbers of Escherichia coli with normal enzymatic activity, which was replaced by atypical forms of E. coli, Enterobacter spp. and fungi of the genus Candida, and, during treatment with GA, by atypical forms of E. coli, Proteus spp., Parvimonas micra. These differences indicate the effect of the therapy on the intestinal microbiota composition.

Keywords:

autoimmunity
multiple sclerosis
dysbiosis
intestinal microbiota
disease-modifying drugs

Authors:

Abdurasulova I.N.

FSBSI «Institute of Experimental Medicine», Moscow

Tarasova E.A.

FGBNU «Institut eksperimentalnoĭ meditsiny»;
OOO Nauchno-issledovatelskaja laboratorija «Diagnostika»

Nikiforova I.G.

Institut mozga cheloveka imeni N.P. Bekhterevoĭ RAN, Sankt-Peterburg

Il'ves A.G.

Ivashkova E.V.

Institut mozga cheloveka im. N.P. Behterevoĭ RAN, Sankt-Peterburg

Matsulevich A.V.

Institute of Experimental Medicine, St-Petersburg, Russia

Tatarinov A.E.

Institute of Experimental Medicine, St-Petersburg, Russia

Shangina L.V.

Institute of Experimental Medicine, St-Petersburg, Russia

Ermolenko E.I.

FGBNU «Institut eksperimentalnoĭ meditsiny»

Klimenko V.M.

Stoliarov I.D.

Suvorov A.N.

Institute of Experimental Medicine, Federal agency of scientific organizations, St.-Petersburg, Russia, 197376

Close metadata

References:

  1. Lassmann H, van Horssen J. The molecular basis f neurodegeneration in multiple sclerosis. FEBS Lett. 2011;585(23):3715-3723. https://doi.org/10.1016/j.febslet.2011.08.004
  2. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci. 2012;13(7):507-514. https://doi.org/10.1038/nrn3275
  3. Boĭko AN, Stolyarov ID, Sidorenko TV, Kulakova OV, Kol’iak EV, Petrov AM, Il’ves AG, Nikiforova IG, Favorova OO, Gusev EI. Pathogenetic treatment of multiple sclerosis: the present and the future. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2009;109(7-2):90-99. (In Russ.)
  4. Stratton CW, Wheldon DB. Multiple sclerosis: An infectious syndrome involving Chlamydophila pneumoniae. Trends Microbiol. 2006;14(11):474-479. https://doi.org/10.1016/j.tim.2006.09.002
  5. Berer K, Krishnamoorthy G. Microbial view of central nervous system autoimmunity. FEBS Lett. 2014;588(22):4207-4213. https://doi.org/10.1016/j.febslet.2014.04.007
  6. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331(6015):337-341. https://doi.org/10.1126/science.1198469
  7. Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol. 2010;28:623-667. https://doi.org/10.1146/annurev-immunol-030409-101330
  8. Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, Mulder I, Lan A, Bridonneau C, Rochet V, Pisi A, De Paepe M, Brandi G, Eberl G, Snel J, Kelly D, Cerf-Bensussan N. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31(4):677-689. https://doi.org/10.1016/j.immuni.2009.08.020
  9. Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4(4):337-349. https://doi.org/10.1016/j.chom.2008.09.009
  10. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci. 2011;12:453-466. https://doi.org/10.1038/nrn3071
  11. Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun. 2014;38:1-12. https://doi.org/10.1016/j.bbi.2013.12.015
  12. Abdurasulova IN, Tarasova EA, Ermolenko EI, Eliseev AV, Matsulevich AV, Bisaga GN, Skulyabin DI, Suvorov AN, Klimenko VM. Multiple sclerosis is associated with altered quantitative and qualitative composition of intestinal microbiota. Medizinskii Academicheskii Zurnal. 2015;15(3):55-67. (In Russ.)
  13. Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, Chihara N, Tomita A, Sato W, Kim SW, Morita H, Hattori M, Yamamura T. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonginf to Clostridia XIVa and IV clusters. PLoS One. 2015;10(9):0137429. https://doi.org/10.1371/journal.pone.0137429
  14. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L, Weiner HL. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7:12-15. https://doi.org/10.1038/ncomms12015
  15. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen X, Weinshenker BG, Rodriguez M, Kantarci OH, Nelson H, Murray JA, Mangalam AK. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6: 28484. https://doi.org/10.1038/srep28484
  16. Levinthal DJ, Rahman F, Nusrat S, O’Leary M, Heyman R, Bielefeldt K. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;319201. https://doi.org/10.1155/2013/319201
  17. Nordenbo AM, Andersen JR, Andersen JT. Disturbances of ano-rectal function in multiple sclerosis. J Neurol. 1996;243:445-451.
  18. Norton C, Chelvanayagam S. Bowel problems and coping strategies in people with multiple sclerosis. Br J Nurs. 2010;19(4):220-226. https://doi.org/10.12968/bjon.2010.19.4.46783
  19. Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, Venkatesan A, Fraser CM, Mowry EM. Gut microbiota in multiple sclerosis: possible influence of immunomodulators. J Investig Med. 2015;63(5):729-734. https://doi.org/10.1097/JIM.0000000000000192
  20. Rumah KR, Vartanian TK, Fischetti VA. Oral multiple sclerosis drugs inhibit the in vitro growth of epsilon toxin producing gut bacterium. Clostridium perfringens Front Cell Infect Microbiol. 2017;7:11. https://doi.org/10.3389/fcimb.2017.00011
  21. Krogh K, Christensen P, Sabroe S, Laurberg S. Neurogenic bowel dysfunction score. Spinal Cord. 2006;44:625-631. https://doi.org/10.1038/sj.sc.3101887
  22. Ermolenko E, Gromova L, Borschev Yu, Voeikova A, Karaseva A, Ermolenko K, Gruzdkov A, Suvorov A. Influence of different probiotic lactic acid bacteria on microbiota and metabolism of rats with dysbiosis. Biosci Microbiota Food Health. 2013;32(2):41-49. https://doi.org/10.12938/bmfh.32.41
  23. Reddy BL, Saier MH. Autism and our intestinal microbiota. J Mol Microbiol Biotechnol. 2015;25(1):51-55. https://doi.org/10.1159/000375303
  24. Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K, Hirayama M. Progression of Parkinson’s disease is associated with gut dysbiosis: Two-year follow-up study. PLoS One. 2017;12(11):0187307. https://doi.org/10.1371/journal.pone.0187307
  25. Alkasir R, Li J, Li X, Jin M, Zhu B. Human gut microbiota: the links with dementia development. Protein Cell. 2017;8(2):90-102. https://doi.org/10.1007/s13238-016-0338-6
  26. Riccio P, Rossano R. Nutrition facts in multiple sclerosis. ASN Neuro. 2015;7(1):1-20. https://doi.org/10.1177/1759091414568185
  27. Kim S, Covington A, Pamer EG. The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017;279(1):90-105. https://doi.org/10.1111/imr.12563
  28. Cosorich I, Dalla-Costa G, Sorini C, Ferrarese R, Messina MJ, Dolpady J, Radice E, Mariani A, Testoni PA, Canducci F, Comi G, Martinelli V, Falcone M. High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci Adv. 2017;3(7): 1700492. https://doi.org/10.1126/sciadv.1700492
  29. Christiansen SH, Murphy RA, Juul-Madsen K, Fredborg M, Hvam ML, Axelgaard E, Skovdal SM, Meyer RL, Sørensen UBS, Möller A, Nyengaard JR, Nørskov-Lauritsen N, Wang M, Gadjeva M, Howard KA, Davies JC, Petersen E, Vorup-Jensen T. The immunomodulatory drug Glatiramer Acetate is also an effective antimicrobial agent that kills gram-negative bacteria. Sci Rep. 2017;7(1):15653. https://doi.org/10.1038/s41598-017-15969-3
  30. Murphy CT, Hall LJ, Hurley G, Quinlan A, MacSharry J, Shanahan F, Nally K, Melgar S. The sphingosine-1-phosphate analogue FTY720 impairs mucosal immunity and clearance of the enteric pathogen Citrobacter rodentium. Infect Immun. 2012;80(8):2712-2723. https://doi.org/10.1128/IAI.06319-11
  31. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi R H, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum. ISME J. 2007;1(5):403-418. https://doi.org/10.1038/ismej.2007.52
  32. Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM, Laughlin RC, Gomez G, Wu J, Lawhon SD, Popova IE, Parikh SJ, Adams LG, Tsolis RM, Stewart VJ, Baumler A.J. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science. 2013;339(6120):708-711. https://doi.org/10.1126/science.1232467
  33. Fraga-Silva TF, Mimura LA, Marchetti CM, Chiuso-Minicucci F, França TG, Zorzella-Pezavento SF, Venturini J, Arruda MS, Sartori A. Experimental autoimmune encephalomyelitis development is aggravated by Candida albicans infection. J Immunol Res. 2015;635-652. https://doi.org/10.1155/2015/635052
  34. Pisa D, Alonso R, Jiménez-Jiménez FJ, Carrasco L. Fungal infection in cerebrospinal fluid from some patients with multiple sclerosis. Eur J Clin Microbiol Infect Dis. 2013;32(6):795-801. https://doi.org/10.1007/s10096-012-1810-8
  35. Buscarinu MC, Cerasoli B, Annibali V, Policano C, Lionetto L, Capi M, Mechelli R, Romano S, Fornasiero A, Mattei G, Piras E, Angelini DF, Battistini L, Simmaco M, Umeton R, Salvetti M, Ristori G. Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study. Mult Scler. 2017;23(3):442-446. https://doi.org/10.1177/1352458516652498
  36. Gutwinski S, Erbe S, Münch C, Janke O, Müller U, Haas J. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology. 2010;74(6):521-523. https://doi.org/10.1212/WNL.0b013e3181cef810
  37. Round JL, Mazmanian S. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA. 2010;107(27):12204-12209. https://doi.org/10.1073/pnas.0909122107
  38. Hooper LV, Stappenbeck TS, Hong CV, Gordon JI. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol. 2003;4(3):269-273. https://doi.org/10.1038/ni888
  39. Shahi SK, Freedman SN, Mangalam AK. Gut microbiom in multiple sclerosis: Th players involved and the roles they play. Gut microbes. 2017;8(6):607-615. https://doi.org/10.1080/19490976.2017.1349041
  40. Purcell RV, Visnovska M, Biggs PJ, Schmeier S, Frizelle FA. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci Rep. 2017;7(1):11590. https://doi.org/10.1038/s41598-017-11237-6
  41. Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, Spencer CM, Lynch SV, Zamvil SS, Waubant E; US Network of Pediatric MS Centers. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neurol. 2016;16(1):182. https://doi.org/10.1186/s12883-016-0703-3
  42. Branton WG, Lu JQ, Surette MG, Holt RA, Lind J, Laman JD, Power C. Brain microbiota disruption within inflammatory demyelinating lesions in multiple sclerosis. Sci Rep. 2016;6:37344. https://doi.org/10.1038/srep37344
  43. Abdurasulova IN, Ermolenko EI, Matsulevich AV, Abdurasulova KO, Tarasova EA, Kudryavtsev IV, Bisaga GN, Suvorov AN, Klimenko VM. Effects of probiotic Enterococci and Glatiramer Acetate on the severity of experimental allergic encephalomyelitis in rats. Neurosci Behav Physiol. 2017;47(7):866-876. (In Russ.) https://doi.org/10.1007/s11055-017-0484-1
  44. Fleck AK, Schuppan D, Wiendl H, Klotz L. Gut-CNS-axis as possibility to modulate inflammatory disease activity-implications for multiple sclerosis. Int J Mol Sci. 2017;18(7):1526. https://doi.org/10.3390/ijms18071526
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.